New treatment strategies for multiple myeloma

Seminars in Hematology

Volumn 41, Issue SUPPL. 7, 2004, Pages 2-8

  Hussein, Mohamad A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; AMOXICILLIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ALOPECIA; ANEMIA; ANTIANGIOGENIC ACTIVITY; BACTERIAL INFECTION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PARESTHESIA; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; VIRUS INFECTION; VOMITING;

EID: 10444263080     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2004.09.002     Document Type: Article

References (39)

1. N.R. Agrawal, M.A. Hussein, P. Elson Pegylated doxorubicin (D), vincristine (V), reduced frequency dexamethasone (D) and thalidomide (T) (DVd-T) in newly diagnosed (Nmm) and relapsed/refractory (Rmm) multiple myeloma patients. 2003 Presented at the 45th Annual Meeting of the American Society of Hematology, San Diego, CA, December 6-9
2. R. Alexanian, B. Barlogie, S. Tucker VAD-based regimens as primary treatment for multiple myeloma Am J Hematol 33 1990 86 89
3. B. Barlogie, L. Smith, R. Alexanian Effective treatment of advanced multiple myeloma refractory to alkylating agents N Engl J Med 310 1984 1353 1356
4. G. Berry, M. Billingham, E. Alderman The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin Ann Oncol 9 1998 711 716
5. J. Blade, D.H. Vesole, G. Morie Transplantation for multiple myeloma Who, when, how often? Blood 102 2003 3469 3470
6. H.P. Browman, A. Belch, J. Skillings Modified adriamycin-vincristine- dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma an NCI (Canada) pilot study Br J Haematol 82 1992 555 559
7. D. Chauhan, H. Uchiyama, Y. Akbarali Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B Blood 87 1996 1104 1112
8. J.S. Damiano, A.E. Cress, L.A. Hazlehurst Cell adhesion mediated drug resistance (CAM-DR) Role of integrins and resistance to apoptosis in human myeloma cell lines Blood 93 1999 1658 1667
9. M.A. Dimopoulos, A. Pouli, K. Zervas Prospective randomized comparison of vincristine, doxorubicin, and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma Ann Oncol 14 2003 1039 1044
10. D. Farray, S. Andresen, M.A. Karam Slow incremental dosing of thalidomide improves tolerance and duration of therapy in myeloma patients Proc Am Soc Clin Oncol 21 2002 276a (abstr)
11. A. Gabizon, R. Catane, B. Uziely Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res 54 1994 987 992
12. A. Gabizon, F. Martin Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours Drugs 54 suppl 4 1997 15 21
13. R. Garcia-Sanz, M.I. Gonzalez-Fraile, M. Sierra The combination of thalidomide, cyclophosphamide, and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma Hematol J 3 2002 43 48
14. M. Hallek, P.L. Bergsagel, K.C. Anderson Multiple myeloma Increasing evidence for a multistep transformation process Blood 91 1998 3 21
15. + subset J Exp Med 187 1998 1885 1892
16. T. Hideshima, D. Chauhan, Y. Shima Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 2000 2943 2950
17. M.A. Hussein, P. Elson, E.A. Tsoe Doxil (D), vincristine (V), Decadron (d) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma (RMM) Blood 100 2002 403a (abstr)
18. M.A. Hussein, J.V. Juturi, I. Lieberman Multiple myeloma Present and future Curr Opin Oncol 14 2002 31 35
19. Hussein MA, Rifkin R, Gregory SA, et al. DVd versus VAd in the treatment of patients with newly diagnosed multiple myeloma (n-MM): An update from a randomized multicenter trial. Presented at the 45th Annual Meeting of the American Society of Hematology, San Diego, CA, December 6-9, 2003
20. M.A. Hussein, L. Wood, E. Hsi A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma Cancer 95 2002 2160 2168
21. International Myeloma Working Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders A report of the International Myeloma Working Group Br J Haematol 121 2003 749 757
22. A. Jemal, R.C. Tiwari, T. Murray Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
23. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 1.2004. Available at: http://www.nccn.org/ physician_gls/f_guidelines.html. Accessed April 5, 2004
24. M.E.R. O'Brien, N. Wigler, M. Inbar Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann Oncol 15 2004 440 449
25. N. Raje, K. Anderson Thalidomide--A revival story N Engl J Med 341 1999 1606 1609
26. Rajkumar SV, Blood E, Vesole DH, et al. A randomized phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): A trial coordinated by the Eastern Cooperative Oncology Group. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004
27. S.V. Rajkumar, R. Fonseca, A. Dispenzieri Thalidomide in the treatment of relapsed multiple myeloma Mayo Clin Proc 75 2000 897 901
28. S.V. Rajkumar, S. Hayman, M.A. Gertz Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma J Clin Oncol 20 2002 4319 4323
29. D. Ribatti, A. Vacca, B. Nico Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma Br J Cancer 79 1999 451 455
30. Rifkin RM, Hussein MA, Gregory SA, et al. Final results: Multicenter trial of DVd vs VAd in newly diagnosed multiple myeloma. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004
31. 2 Ann Oncol 11 2000 1029 1033
32. D. Samson, E. Gaminara, A. Newland Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma Lancet 2 1989 882 885
33. S. Singhal, J. Mehta, R. Desikan Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1999 1565 1571
34. M. Urashima, D. Chauhan, H. Uchiyama CD40 ligand triggered interleukin-6 secretion in multiple myeloma Blood 85 1995 1903 1912
35. M. Urashima, A. Ogata, D. Chauha Transforming growth factor-beta1 Differential effects on multiple myeloma versus normal B cells Blood 87 1996 1928 1938
36. A. Vacca, D. Ribatti, L. Roncali Bone marrow angiogenesis and progression in multiple myeloma Br J Haematol 87 1994 503 508
37. D. Weber, K. Rankin, M. Gavino Thalidomide alone or with dexamethasone for previously untreated multiple myeloma J Clin Oncol 21 2003 16 19
38. K. Zervas, M.A. Dimopoulos, E. Hatzicharissi Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD Doxil) A phase II multicenter study Ann Oncol 15 2004 134 138
39. S. Zhou, P. Kestell, M.D. Tingle Thalidomide in cancer treatment A potential role in the elderly? Drugs Aging 19 2002 85 100